Stocks and Investing
Stocks and Investing
Fri, May 4, 2018
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Thu, May 3, 2018
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Matthew Luchini Maintained (BLUE) at Buy with Decreased Target to $216 on, May 3rd, 2018
Matthew Luchini of BMO Capital, Maintained "bluebird bio, Inc." (BLUE) at Buy with Decreased Target from $222 to $216 on, May 3rd, 2018.
Matthew has made no other calls on BLUE in the last 4 months.
There are 3 other peers that have a rating on BLUE. Out of the 3 peers that are also analyzing BLUE, all agree with Matthew's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Matthew Harrison of "Morgan Stanley" Maintained at Hold with Increased Target to $209 on, Wednesday, March 21st, 2018
- Ying Huang of "B of A Securities" Maintained at Hold with Increased Target to $218 on, Thursday, February 22nd, 2018
- Michael Schmidt of "Leerink Swann" Downgraded from Buy to Hold on, Thursday, January 25th, 2018
Contributing Sources